Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifeTech ScientificHKSE:01302 -1.42%95 Interest Coverage is 755.16 as of Dec. 2025, which is 324% above its 10-year median of 177.95. GuruFocus rates HKSE:01302 with a GF Score™ of 95/100 and a GF Value™ of HK$2.12 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 464 Medical Devices & Instruments companies, LifeTech Scientific ranks better than 90.3% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. LifeTech Scientific's
Operating Income
for the
six
months ended in Dec. 2025 was HK$175 Mil. LifeTech Scientific's Interest Expense for the
six
months ended in Dec. 2025 was HK$-0 Mil.
LifeTech Scientific's interest coverage for the quarter that ended in Dec. 2025 was 755.16.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. LifeTech Scientific Corp has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for LifeTech Scientific's Interest Coverage or its related term are showing as below:
HKSE:01302'
s Interest Coverage Range Over the Past 10 Years
Min: 1.6 Med: 177.95 Max: 837.49
Current: 836.62
HKSE:01302's Interest Coverage is ranked better than 90.3% of 464
companies
in the Medical Devices & Instruments industry
Industry Median: 16.08
vs HKSE:01302: 836.62
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
LifeTech Scientific Interest Coverage Related Terms
LifeTech Scientific Interest Coverage Historical Data
* Premium members only.
The historical data trend for LifeTech Scientific's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKSE:01302 vs ABT, SYK, MDT: Interest Coverage Comparison
For the Medical Devices subindustry, LifeTech Scientific's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LifeTech Scientific Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LifeTech Scientific's Interest Coverage distribution charts can be found below:
* The bar in red indicates where LifeTech Scientific's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LifeTech Scientific (HKSE:01302) has a Interest Coverage of 755.16 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on LifeTech Scientific and its competitors. This is 324% above median its historical median of 177.95. Over the past decade, LifeTech Scientific's Interest Coverage has ranged from 1.60 to 837.49. According to the industry distribution chart, LifeTech Scientific ranks #45 out of 464 companies in the Medical Devices & Instruments industry, placing it in the top 9.7%.
Is LifeTech Scientific's Interest Coverage too high?
LifeTech Scientific's current Interest Coverage of 755.16 is 324% above median its 10-year median of 177.95. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 837.49. The Medical Devices & Instruments industry median Interest Coverage is 16.08. LifeTech Scientific's value of 755.16 is 4596.3% above this industry median. Based on the distribution chart, LifeTech Scientific ranks #45 out of 464 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LifeTech Scientific has a GF Score™ of 95/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LifeTech Scientific's Interest Coverage compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, LifeTech Scientific ranks #45 out of 464 companies for Interest Coverage. This places LifeTech Scientific in the top 10% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 16.08. LifeTech Scientific's value of 755.16 is 4596.3% above this benchmark. Historically, LifeTech Scientific's own Interest Coverage has ranged from 1.60 to 837.49 over the past decade. While the company's 10-year median is 177.95 vs. the industry median of 16.08, LifeTech Scientific has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.08, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LifeTech Scientific's current Interest Coverage of 755.16 is 4596.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on LifeTech Scientific and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LifeTech Scientific's current Interest Coverage is 755.16, which is 324% above median its own 10-year median of 177.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeTech Scientific stock overvalued right now?
Based on GuruFocus' analysis, LifeTech Scientific (HKSE:01302) is currently considered Possible Value Trap. The stock's GF Value™ is HK$2.12, compared to a current price of HK$1.39 — trading 34.4% below its estimated fair value. The current Interest Coverage is 755.16, which is 324% above median its 10-year median of 177.95 and 4596.3% above the Medical Devices & Instruments industry median of 16.08. LifeTech Scientific's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For LifeTech Scientific (HKSE:01302), the current Interest Coverage is 755.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LifeTech Scientific (HKSE:01302) Overvalued in 2026?
Based on GuruFocus' analysis, LifeTech Scientific stock appears to be undervalued.
The current stock price of HK$1.39 is trading 34.4% below its estimated GF Value™ of HK$2.12.
GuruFocus considers LifeTech Scientific to be Possible Value Trap.
Key valuation signals for HKSE:01302:
Interest Coverage: 755.16 (324% above median its 10-year median of 177.95)
GF Value™: HK$2.12 vs. price of HK$1.39 (34.4% below fair value)
Industry Position: 4596.3% above the Medical Devices & Instruments median (#45 of 464)
No single metric tells the full story. See the HKSE:01302 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LifeTech Scientific Corp develops and manufactures also responsible for marketing of minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The firm operates in three areas: the Structural heart diseases business, the Peripheral vascular diseases business, and the Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral Vascular Diseases business segment. Geographically, it derives a majority of its revenue from Mainland China, and it also has its presence in Europe, Asia, excluding mainland China and India, India, South America, Africa, and Others.
95GF Score
Get the complete analysis for HKSE:01302
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01302 has been successfully added to your 
